The Barriers and Facilitators of Different Stakeholders When Deprescribing Benzodiazepine Receptor Agonists in Older Patients-A Systematic Review

Research output: Contribution to journalReviewResearchpeer-review

Standard

The Barriers and Facilitators of Different Stakeholders When Deprescribing Benzodiazepine Receptor Agonists in Older Patients-A Systematic Review. / Rasmussen, Anja Fog; Poulsen, Sarah Sonne; Oldenburg, Lykke Ida Kaas; Vermehren, Charlotte.

In: Metabolites, Vol. 11, No. 4, 254, 2021.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Rasmussen, AF, Poulsen, SS, Oldenburg, LIK & Vermehren, C 2021, 'The Barriers and Facilitators of Different Stakeholders When Deprescribing Benzodiazepine Receptor Agonists in Older Patients-A Systematic Review', Metabolites, vol. 11, no. 4, 254. https://doi.org/10.3390/metabo11040254

APA

Rasmussen, A. F., Poulsen, S. S., Oldenburg, L. I. K., & Vermehren, C. (2021). The Barriers and Facilitators of Different Stakeholders When Deprescribing Benzodiazepine Receptor Agonists in Older Patients-A Systematic Review. Metabolites, 11(4), [254]. https://doi.org/10.3390/metabo11040254

Vancouver

Rasmussen AF, Poulsen SS, Oldenburg LIK, Vermehren C. The Barriers and Facilitators of Different Stakeholders When Deprescribing Benzodiazepine Receptor Agonists in Older Patients-A Systematic Review. Metabolites. 2021;11(4). 254. https://doi.org/10.3390/metabo11040254

Author

Rasmussen, Anja Fog ; Poulsen, Sarah Sonne ; Oldenburg, Lykke Ida Kaas ; Vermehren, Charlotte. / The Barriers and Facilitators of Different Stakeholders When Deprescribing Benzodiazepine Receptor Agonists in Older Patients-A Systematic Review. In: Metabolites. 2021 ; Vol. 11, No. 4.

Bibtex

@article{e26690294b7a4b55abc8ecbffc578480,
title = "The Barriers and Facilitators of Different Stakeholders When Deprescribing Benzodiazepine Receptor Agonists in Older Patients-A Systematic Review",
abstract = "Treatment of older patients with benzodiazepines and Z-drugs (BZRA) is associated with an increased risk of side effects. However, this treatment is still used among these patients. Deprescribing can be a tool to reduce inappropriate medication. This review aims to identify and compare barriers and facilitators of stakeholders involved in BZRA deprescribing in older patients and uncover potential gaps in the research field. The search was conducted in PubMed, EMBASE, PsycINFO, and Cochrane Library. Ten articles based on qualitative data on BZRA deprescribing in older patients (>= 65 years) published between 2005-2020 were included. Six articles referred to patients as stakeholders, two referred to physicians, and one to nurses and caregivers, respectively, indicating a need for more studies in the field. More barriers than facilitators were identified. Important findings were the patient willingness to deprescribe BZRA compared to physicians, who did not mention deprescribing to patients due to barriers such as expected patient resistance. Nurses mentioned barriers like lack of knowledge and the feeling that their options were not valued by physicians; education was found to be a shared deprescribing facilitator among the stakeholders. Being aware of deprescribing barriers and facilitators can be helpful in future successful deprescribing interventions.",
keywords = "deprescribing, barriers, facilitators, older patients, benzodiazepines, Z-drugs, BZRA",
author = "Rasmussen, {Anja Fog} and Poulsen, {Sarah Sonne} and Oldenburg, {Lykke Ida Kaas} and Charlotte Vermehren",
year = "2021",
doi = "10.3390/metabo11040254",
language = "English",
volume = "11",
journal = "Metabolites",
issn = "2218-1989",
publisher = "M D P I AG",
number = "4",

}

RIS

TY - JOUR

T1 - The Barriers and Facilitators of Different Stakeholders When Deprescribing Benzodiazepine Receptor Agonists in Older Patients-A Systematic Review

AU - Rasmussen, Anja Fog

AU - Poulsen, Sarah Sonne

AU - Oldenburg, Lykke Ida Kaas

AU - Vermehren, Charlotte

PY - 2021

Y1 - 2021

N2 - Treatment of older patients with benzodiazepines and Z-drugs (BZRA) is associated with an increased risk of side effects. However, this treatment is still used among these patients. Deprescribing can be a tool to reduce inappropriate medication. This review aims to identify and compare barriers and facilitators of stakeholders involved in BZRA deprescribing in older patients and uncover potential gaps in the research field. The search was conducted in PubMed, EMBASE, PsycINFO, and Cochrane Library. Ten articles based on qualitative data on BZRA deprescribing in older patients (>= 65 years) published between 2005-2020 were included. Six articles referred to patients as stakeholders, two referred to physicians, and one to nurses and caregivers, respectively, indicating a need for more studies in the field. More barriers than facilitators were identified. Important findings were the patient willingness to deprescribe BZRA compared to physicians, who did not mention deprescribing to patients due to barriers such as expected patient resistance. Nurses mentioned barriers like lack of knowledge and the feeling that their options were not valued by physicians; education was found to be a shared deprescribing facilitator among the stakeholders. Being aware of deprescribing barriers and facilitators can be helpful in future successful deprescribing interventions.

AB - Treatment of older patients with benzodiazepines and Z-drugs (BZRA) is associated with an increased risk of side effects. However, this treatment is still used among these patients. Deprescribing can be a tool to reduce inappropriate medication. This review aims to identify and compare barriers and facilitators of stakeholders involved in BZRA deprescribing in older patients and uncover potential gaps in the research field. The search was conducted in PubMed, EMBASE, PsycINFO, and Cochrane Library. Ten articles based on qualitative data on BZRA deprescribing in older patients (>= 65 years) published between 2005-2020 were included. Six articles referred to patients as stakeholders, two referred to physicians, and one to nurses and caregivers, respectively, indicating a need for more studies in the field. More barriers than facilitators were identified. Important findings were the patient willingness to deprescribe BZRA compared to physicians, who did not mention deprescribing to patients due to barriers such as expected patient resistance. Nurses mentioned barriers like lack of knowledge and the feeling that their options were not valued by physicians; education was found to be a shared deprescribing facilitator among the stakeholders. Being aware of deprescribing barriers and facilitators can be helpful in future successful deprescribing interventions.

KW - deprescribing

KW - barriers

KW - facilitators

KW - older patients

KW - benzodiazepines

KW - Z-drugs

KW - BZRA

U2 - 10.3390/metabo11040254

DO - 10.3390/metabo11040254

M3 - Review

C2 - 33923956

VL - 11

JO - Metabolites

JF - Metabolites

SN - 2218-1989

IS - 4

M1 - 254

ER -

ID: 272373090